HK24595A - Reduction of side effects of cancer therapy - Google Patents

Reduction of side effects of cancer therapy

Info

Publication number
HK24595A
HK24595A HK24595A HK24595A HK24595A HK 24595 A HK24595 A HK 24595A HK 24595 A HK24595 A HK 24595A HK 24595 A HK24595 A HK 24595A HK 24595 A HK24595 A HK 24595A
Authority
HK
Hong Kong
Prior art keywords
interferon
patient
accordance
human
treatment
Prior art date
Application number
HK24595A
Other languages
English (en)
French (fr)
Inventor
M. Cummins Joesph
Original Assignee
Amarillo Cell Culture Company, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarillo Cell Culture Company, Incorporated filed Critical Amarillo Cell Culture Company, Incorporated
Publication of HK24595A publication Critical patent/HK24595A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

  1. Verwendung von Interferon zur Herstellung eines Medikamentes in einer bukkalen Dosierungsform, die zur Freisetzung von Interferon in eines Patienten Mund für einen Kontakt mit des Patienten oraler und paryngealer Schleimhaut definiert ist, um die toxischen Nebeneffekte zu verringern, die aus der Verabreichung einer Krebstherapie unter Verwendung chemotherapeutischer Agenzien oder Strahlenbehandlung im eine solche Therapie zur Krebsbehandlung erhaltenden Patienten resultieren, wobei die bukkale Dosierungsform Interferon und einen pharmazeutisch akzeptablen Träger hierfür umfaßt und 0,22 bis 11 IU Interferon pro kg (0,1 bis 5 IU/lb) Patientenkörpergewicht erbringt.
  2. Verwendung nach Anspruch 1, in welcher die bukkale Dosierungsform so hergestellt wird, daß sie 2,2 bis 3,3 IU Interferon pro kg (1 bis 1,5 IU/lb) Patientenkörpergewicht erbringt.
  3. Verwendung von Interferon nach Anspruch 1 oder 2, in welcher das Interferon ein nicht-menschliches Interferon ist.
  4. Verwendung von Interferon nach Anspruch 1 oder 2, in welcher das Interferon Alpha-Interferon ist.
  5. Verwendung von Interferon nach Anspruch 1 oder 2, in welcher das Interferon ein von menschlichen Leukozyten erzeugtes Interferon ist.
  6. Verwendung von Interferon nach Anspruch 1 oder 2, in welcher das Interferon ein Beta-Interferon ist.
  7. Verwendung von Interferon nach Anspruch 1 oder 2, in welcher der pharmazeutisch akzeptable Träger so ausgewählt ist, daß das Medikament in einer festen Dosierungsform vorliegt, die zur Auflösung in Kontakt mit Speichel im Mund des Patienten definiert ist.
  8. Verwendung von Interferon nach Anspruch 1 oder 2, in welcher der pharmazeutisch akzeptable Träger so ausgewählt ist, daß das Medikament in einer flüssigen Dosierungsform vorliegt.
HK24595A 1988-01-06 1995-02-23 Reduction of side effects of cancer therapy HK24595A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/141,621 US5017371A (en) 1988-01-06 1988-01-06 Method for reducing side effects of cancer therapy

Publications (1)

Publication Number Publication Date
HK24595A true HK24595A (en) 1995-03-03

Family

ID=22496471

Family Applications (1)

Application Number Title Priority Date Filing Date
HK24595A HK24595A (en) 1988-01-06 1995-02-23 Reduction of side effects of cancer therapy

Country Status (11)

Country Link
US (1) US5017371A (de)
EP (1) EP0396616B1 (de)
JP (1) JP2813017B2 (de)
AT (1) ATE104152T1 (de)
AU (1) AU630598B2 (de)
CA (1) CA1336398C (de)
DE (1) DE68914644T2 (de)
DK (1) DK160690A (de)
HK (1) HK24595A (de)
HU (1) HU206987B (de)
WO (1) WO1989006139A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102870A (en) * 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
NZ237688A (en) * 1990-04-19 1993-01-27 Res Dev Foundation Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
CA2233544A1 (en) * 1995-10-04 1997-04-10 Schering Corporation Combination temozolomide and alpha-ifn for the treatment of advanced cancer
US7294332B2 (en) 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
US20030108519A1 (en) * 1996-05-09 2003-06-12 Pharma Pacific Pty Ltd. Therapeutic applications of high dose in terferon
CA2253971A1 (en) 1996-05-09 1997-11-13 Pharma Pacific Pty.Ltd. Use of high dose interferon by oralmucosal contact to treat viral infections and neoplastic conditions
WO1998035659A1 (en) * 1997-02-18 1998-08-20 Lxr Biotechnology Inc. Bak promotor expression system
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
EP1237567B1 (de) * 1999-12-09 2005-08-03 Chiron Corporation Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
JP2006506964A (ja) * 2002-06-12 2006-03-02 リサーチ　ディベロップメント　ファンデーション 治療剤としての免疫毒素及びその利用
WO2004000266A1 (en) * 2002-06-20 2003-12-31 Yuriy Vasilievich Tyagotin Method for oral transmucosal delivery of interferon
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
JP2008528633A (ja) * 2005-02-01 2008-07-31 リサーチ ディベロップメント ファウンデーション Ｂｌｙｓレセプターを標的化するためのｂｌｙｓ融合タンパク質およびｂ細胞増殖性疾患の処置方法
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
AU2007205545B9 (en) * 2006-01-12 2012-10-18 Hokusan Co. Ltd. Oral composition containing interferon-alpha
US20090203661A1 (en) * 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN102655869B (zh) 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
US9642893B2 (en) 2013-07-03 2017-05-09 Joseph Cummins Method for reducing injury and stabilizing muscle using orally administered interferon
EP3368064B1 (de) 2015-10-29 2021-05-19 CLS Therapeutics Limited Verwendung von dnase zur verbesserung der sicherheit und wirksamkeit einer krebschemotherapie

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
ZA754725B (en) * 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DK485977A (da) * 1977-11-01 1979-05-02 Ess Foodeksport Fremgangsmaade til udvinding af et biologisk aktivt materiale fra svineblodfraktioner
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
EP0058192A1 (de) * 1980-08-22 1982-08-25 University of Illinois Foundation Abgabe biologisch aktiver komponenten aus interferon isolierten der heterologischen species
EP0080879B1 (de) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4649075A (en) * 1984-08-09 1987-03-10 Leonora Jost Transdermal and transmucosal vortexed foam devices and the method of making
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0177342A3 (de) * 1984-10-04 1987-12-02 Genentech, Inc. Orale Formulierungen therapeutischer Proteine
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease

Also Published As

Publication number Publication date
JP2813017B2 (ja) 1998-10-22
DE68914644D1 (de) 1994-05-19
DE68914644T2 (de) 1994-07-21
HUT56720A (en) 1991-10-28
WO1989006139A1 (en) 1989-07-13
EP0396616B1 (de) 1994-04-13
CA1336398C (en) 1995-07-25
DK160690D0 (da) 1990-07-03
EP0396616A1 (de) 1990-11-14
US5017371A (en) 1991-05-21
AU630598B2 (en) 1992-11-05
AU2941489A (en) 1989-08-01
HU206987B (en) 1993-03-01
JPH03504375A (ja) 1991-09-26
EP0396616A4 (en) 1991-10-16
ATE104152T1 (de) 1994-04-15
HU890950D0 (en) 1991-08-28
DK160690A (da) 1990-07-03

Similar Documents

Publication Publication Date Title
EP0396616B1 (de) Verringerung der nebeneffekte bei der krebstherapie
US5019382A (en) Treatment of immuno-resistant disease with low-dose interferon
US6372218B1 (en) Interferon dosage form and method therefor
CA1323564C (en) Low dosage of interferon to enhance vaccine efficiency
EP0231819B1 (de) Pharmazeutischer Stoff für die Behandlung von myelogener Leukämie
US5215741A (en) Method for prevention of parasite infections
EP0303687B1 (de) Zubereitungen zur verbesserung der adcc-therapien
JPH10511974A (ja) リソチーム二量体の新しい応用
US20030206962A1 (en) Method for treating cancer patients undergoing chemotherapy
JPH05508769A (ja) 細胞培養及び治療に有用なβ―アレチン
EP1790355B1 (de) Propagationsmittel und propagationsverfahren für natürliche killerzelle
AU625431C (en) Improved interferon therapy
EP0619120B1 (de) Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
DK172974B1 (da) Immunoterapeutisk, fast oral interferondosisform samt fremgangsmåde til fremstilling heraf
JPS5888322A (ja) 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法
JPH05271095A (ja) 抗癌剤
CN113440601A (zh) Nk细胞和tfpi联用在防治鼻咽癌中的应用
Boddé Interferon: Will It Live Up to Its Promise?
HK1103987B (en) Propagation agent and propagation method for natural killer cell
JPS5889195A (ja) 標的細胞障害性因子の製造方法
JPH0930985A (ja) リンパ球機能改善剤

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)